Cyclooxygenase‐2 Inhibition and Anti‐Platelet Aggregation Activity of Astaxanthin‐Hydrogel in Comparison to Celecoxib Against Rheumatoid Arthritis in Wistar Rat Model
Biopharmaceutics & Drug Disposition · 2026-04 · 47 (2) · 78-87
DOI: 10.1002/bdd.70027 ↗At a glance
Vergleichsstudie in Biopharmaceutics & Drug Disposition, published online on 2026-02-24. Written by Anzeela Ghaffar and 5 co-authors. Institution: Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan. Major MEDLINE topics: Celecoxib, Arthritis, Rheumatoid, Cyclooxygenase 2 Inhibitors, Arthritis, Experimental. 46 references. The full text is freely available in PubMed Central.
Abstract (original language)
Rheumatoid arthritis is an auto‐immune disease, commonly treated with celecoxib (Cyclooxygenase‐2 inhibitor), which comes with serious cardiovascular threats. Astaxanthin is a natural carotenoid, possessing extraordinary anti‐inflammatory and anti‐platelet aggregation qualities. The aim of this study was to investigate the superlative effects of astaxanthin‐hydrogel to inhibiting the cyclooxygenase‐2 in comparison to celecoxib and its cardiac side‐effects, specifically platelet aggregation. Induction of rheumatoid arthritis was accomplished by type‐II‐collagen/Complete Freund's adjuvant followed by a booster dose of Incomplete Freund's adjuvant and confirmed by arthritic score calculation, CRP and ACCPA tests. Astaxanthin‐hydrogel was subcutaneously injected into the neck and back of arthritic Wistar rats in comparison to oral‐celecoxib. Cyclooxygenase‐2 inhibitory activity was observed by rat ELISA kit and platelet aggregation was monitored by optical chrono‐log aggregometer. Results were compared by statistical analysis, executed through IBMM SPSS. The anti‐inflammatory activity of 20 mg/week astaxanthin‐hydrogel to inhibiting the cyclooxygenase‐2 for 6 weeks in arthritic wistar rats was found more effective in comparison to 20 mg/day celecoxib. Continued use of 40 mg/day celecoxib for 8 weeks has been seen involved with platelet aggregation, whereas the regimen consisting of 20 mg/week astaxanthin‐hydrogel administered with 20 mg/d celecoxib for 8 weeks was observed with no platelet aggregation. Celecoxib monotherapy was found associated with a little risk of platelet aggregation, whereas along with astaxanthin‐hydrogel, no platelet aggregation was found. Notably, astaxanthin‐hydrogel was significant to suppress the cyclooxygenase‐2 in comparison to celecoxib.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
- Department of Pharmacy, The University of Lahore, Sargodha Campus, Sargodha, Pakistan.
ORCID profiles: Anzeela Ghaffar
Cite
APA
Ghaffar, A., Sharif, S., Naveed, Q., Aslam, T., Lodhi, M. S., & Nayila, I. (2026). Cyclooxygenase‐2 Inhibition and Anti‐Platelet Aggregation Activity of Astaxanthin‐Hydrogel in Comparison to Celecoxib Against Rheumatoid Arthritis in Wistar Rat Model. Biopharmaceutics & Drug Disposition, 47(2), 78-87. https://doi.org/10.1002/bdd.70027
Vancouver
Ghaffar A, Sharif S, Naveed Q, Aslam T, Lodhi MS, Nayila I. Cyclooxygenase‐2 Inhibition and Anti‐Platelet Aggregation Activity of Astaxanthin‐Hydrogel in Comparison to Celecoxib Against Rheumatoid Arthritis in Wistar Rat Model. Biopharmaceutics & Drug Disposition. 2026;47(2):78-87. doi:10.1002/bdd.70027
BibTeX
@article{Ghaffar2026,
author = {Ghaffar, Anzeela and Sharif, Sumaira and Naveed, Quindeel and Aslam, Taimoor and Lodhi, Madeeha Shahzad and Nayila, Iffat},
title = {Cyclooxygenase‐2 Inhibition and Anti‐Platelet Aggregation Activity of Astaxanthin‐Hydrogel in Comparison to Celecoxib Against Rheumatoid Arthritis in Wistar Rat Model},
journal = {Biopharmaceutics & Drug Disposition},
year = {2026},
volume = {47},
number = {2},
pages = {78--87},
doi = {10.1002/bdd.70027}
}
EUVIMED